Moffitt logo

Clinical Trials Search

Search Results:

Showing of 50

CLINICAL TRIAL 17263

Phase I Trial of ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 18891

A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 18926

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 19194

A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 50259

Understanding the Dynamic Composition of Immune Subpopulations in the Course of Multiple Myeloma Disease Progression and Emergence of Drug Resistance

Cancer Type: Multiple Myeloma

View Trial Details

CLINICAL TRIAL 19360

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 19722

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 18630

Phase 1/2 Investigator Sponsored Study of Selinexor in Combination with High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 19813

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (Karmma-3)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 20038

Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL 19093

Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma

Cancer Type: Malignant Hematology

View Trial Details